Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Tempus extends data licensing partnership with Recursion through November 2029

Tempus extends data licensing partnership with Recursion through November 2029

BitgetBitget2026/09/21 16:17
  • Tempus extended its multi-year data license partnership with Recursion through November 2029.
  • Deal resets original master agreement fees to committed payments totaling $42 million over three years.
  • Prior structure included discretionary license fees potentially totaling $84 million over the next two years.
  • Separate agreement grants a non-exclusive, worldwide license to Recursion’s RNA foundation model, TxFM.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609210914BIZWIRE_USPR_____20260920_BW789157) on September 21, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Rising energy prices increase inflation risks, Reserve Bank of Australia expected to implement the fourth rate hike of the year next week

As rising energy prices further highlight upward inflation risks, economists state that the Reserve Bank of Australia will raise its key interest rate next week and warn that there could be another hike in November.

智通财经2026/09/22 03:16

AI pharmaceutical company Iambic (IAM.US), supported by Nvidia, applies for US IPO to advance three early-stage cancer drugs

Iambic Therapeutics Inc. has filed for an initial public offering (IPO) in the United States.

智通财经2026/09/22 02:31